Randomized clinical trial of a calcium supplement for improvement of health in dairy cows in early lactation.
Prophylactic Ca supplementation immediately after calving is a common strategy to prevent clinical and subclinical hypocalcemia in parturient dairy cows. The objective of this study was to evaluate the effect of prophylactic administration of an injected Ca supplement on blood Ca concentration at 24 and 48h after treatment, incidence risk of clinical disease and culling, milk production in early lactation, and probability of pregnancy at first insemination. Cows without signs of visible milk fever (n=984) from 7 farms were blocked by parity and randomly assigned to receive either Ca gluconate (35% wt/vol) in combination with Ca glucoheptonate (10% wt/vol; TheraCalcium, Vétoquinol Canada Inc., Lavaltrie, Quebec) or a placebo (medication vehicle solution with no Ca) at first contact with each cow after calving and again 12 to 24h later. Each dose was 120mL injected subcutaneously over 2 sites. Total serum Ca concentration (tCa) was measured from coccygeal blood samples before (time 0) and 24 and 48h after first treatment in a subsample of cows (n=129). Blood β-hydroxybutyrate concentrations were measured from all cows twice between 3 and 16d in milk at weekly visits and cows were evaluated for vaginal discharge once between 28 and 42d in milk. Disease events, production data from the first 3 Dairy Herd Improvement milk tests, reproduction, and culling data were collected from each herd. For cows that had received 1 injection of Ca before the blood sample at 24h (n=95), tCa was significantly higher in the treated cows: mean ± standard error, 2.03±0.03 versus 1.90±0.03mmol/L, accounting for tCa at time of enrollment and a treatment by tCa at enrollment interaction. At 48h, no significant difference was found in tCa between treatment and control (mean ± SE, 2.12±0.02 and 2.10±0.03mmol/L, respectively). Cows treated with the Ca product were significantly less likely to have received intravenous, subcutaneous, or oral supplemental Ca for exhibiting clinical signs of hypocalcemia than control cows (5.0 vs. 8.4%). No effect was found of treatment on retained placenta, metritis, hyperketonemia, prevalence of purulent vaginal discharge, culling from the herd, early lactation production, probability of pregnancy to first artificial insemination, or time to pregnancy. With this subcutaneous prophylactic Ca treatment regimen, blood Ca levels were temporarily increased at 24h after treatment, but no effect was observed of supplemental Ca on the risk of disease or culling, milk production, or reproductive performance.
Department of Population Medicine, University of Guelph, ON, Canada N1G 2W1.
Cynthia L
CL
Miltenburg
Department of Population Medicine, University of Guelph, ON, Canada N1G 2W1.
Todd F
TF
Duffield
Department of Pathobiology, University of Guelph, ON, Canada N1G 2W1.
Dorothee
D
Bienzle
Department of Population Medicine, University of Guelph, ON, Canada N1G 2W1.
Elizabeth L
EL
Scholtz
Department of Population Medicine, University of Guelph, ON, Canada N1G 2W1. Electronic address: sleblanc@uoguelph.ca.
Stephen J
SJ
LeBlanc
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000818:Animals; D002118:Calcium / Q000097:blood*; D002417:Cattle; D002418:Cattle Diseases / Q000453:epidemiology*; D005260:Female; D007774:Lactation / Q000187:drug effects; D008892:Milk; D012098:Reproduction / Q000187:drug effects
D002118:Calcium; D020155:3-Hydroxybutyric Acid
calcium supplement; disease; hypocalcemia; periparturient; transition